<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lucy Catteau</style></author><author><style face="normal" font="default" size="100%">Nicolas Dauby</style></author><author><style face="normal" font="default" size="100%">Marion Montourcy</style></author><author><style face="normal" font="default" size="100%">Bottieau, Emmanuel</style></author><author><style face="normal" font="default" size="100%">Joris Hautekiet</style></author><author><style face="normal" font="default" size="100%">Goetghebeur, Els</style></author><author><style face="normal" font="default" size="100%">Sabrina Van Ierssel</style></author><author><style face="normal" font="default" size="100%">Els Duysburgh</style></author><author><style face="normal" font="default" size="100%">Herman Van Oyen</style></author><author><style face="normal" font="default" size="100%">Chloé Wyndham-Thomas</style></author><author><style face="normal" font="default" size="100%">Dominique Van Beckhoven</style></author><author><style face="normal" font="default" size="100%">Kristof Bafort</style></author><author><style face="normal" font="default" size="100%">Leïla Belkhir</style></author><author><style face="normal" font="default" size="100%">Nathalie Bossuyt</style></author><author><style face="normal" font="default" size="100%">Philippe Caprasse</style></author><author><style face="normal" font="default" size="100%">Vincent Colombie</style></author><author><style face="normal" font="default" size="100%">De Munter, Paul</style></author><author><style face="normal" font="default" size="100%">Jessika Deblonde</style></author><author><style face="normal" font="default" size="100%">Didier Delmarcelle</style></author><author><style face="normal" font="default" size="100%">Mélanie Delvallee</style></author><author><style face="normal" font="default" size="100%">Demeester, Rémy</style></author><author><style face="normal" font="default" size="100%">Thierry Dugernier</style></author><author><style face="normal" font="default" size="100%">Xavier Holemans</style></author><author><style face="normal" font="default" size="100%">Benjamin Kerzmann</style></author><author><style face="normal" font="default" size="100%">Pierre Yves Machurot</style></author><author><style face="normal" font="default" size="100%">Philippe Minette</style></author><author><style face="normal" font="default" size="100%">Jean-Marc Minon</style></author><author><style face="normal" font="default" size="100%">Saphia Mokrane</style></author><author><style face="normal" font="default" size="100%">Catherine Nachtergal</style></author><author><style face="normal" font="default" size="100%">Séverine Noirhomme</style></author><author><style face="normal" font="default" size="100%">Piérard, Denis</style></author><author><style face="normal" font="default" size="100%">Camelia Rossi</style></author><author><style face="normal" font="default" size="100%">Schirvel, Carole</style></author><author><style face="normal" font="default" size="100%">Erica Sermijn</style></author><author><style face="normal" font="default" size="100%">Frank Staelens</style></author><author><style face="normal" font="default" size="100%">Filip Triest</style></author><author><style face="normal" font="default" size="100%">Nina Van Goethem</style></author><author><style face="normal" font="default" size="100%">Jens Van Praet</style></author><author><style face="normal" font="default" size="100%">Anke Vanhoenacker</style></author><author><style face="normal" font="default" size="100%">Roeland Verstraete</style></author><author><style face="normal" font="default" size="100%">Elise Willems</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Hydroxychloroquine</style></keyword><keyword><style  face="normal" font="default" size="100%">mortality</style></keyword><keyword><style  face="normal" font="default" size="100%">observational study</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-10-2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">56</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various&lt;/p&gt;

&lt;p&gt;settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of&lt;/p&gt;

&lt;p&gt;low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19.&lt;/p&gt;

&lt;p&gt;We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital&lt;/p&gt;

&lt;p&gt;surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were&lt;/p&gt;

&lt;p&gt;compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional&lt;/p&gt;

&lt;p&gt;hazards regression with discharge alive as competing risk, adjusted for demographic and clinical&lt;/p&gt;

&lt;p&gt;features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020&lt;/p&gt;

&lt;p&gt;and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ&lt;/p&gt;

&lt;p&gt;group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable&lt;/p&gt;

&lt;p&gt;analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio&lt;/p&gt;

&lt;p&gt;(aHR) = 0.684, 95% confidence interval (CI) 0.617–0.758]. Compared with the no-HCQ group, mortality&lt;/p&gt;

&lt;p&gt;in the HCQ group was reduced both in patients diagnosed ≤5 days ( n = 3975) and &amp;gt; 5 days ( n = 3487)&lt;/p&gt;

&lt;p&gt;after symptom onset [aHR = 0.701 (95% CI 0.617–0.796) and aHR = 0.647 (95% CI 0.525–0.797), respectively].&lt;/p&gt;

&lt;p&gt;Compared with supportive care only, low-dose HCQ monotherapy was independently associated&lt;/p&gt;

&lt;p&gt;with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after&lt;/p&gt;

&lt;p&gt;symptom onset.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><section><style face="normal" font="default" size="100%">106144</style></section></record></records></xml>